Paper Details

  1. Home
  2. Paper Details

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly.

Author: FalseyA R, WalshE E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

PFP-2 respiratory syncytial virus (RSV) vaccine was well-tolerated and relatively immunogenic in frail elderly individuals, although the response rate was slightly lower compared to healthy elderly.
Paper Details　
Original Abstract of the Article :
The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in an open label study in 37 frail institutionalized persons over age 65. Vaccination was well tolerated without significant side-effects. Thirty-six of 37 volunteers completed th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0264-410x(97)00002-9

データ提供：米国国立医学図書館（NLM）

A Protective Shield for the Elderly: Evaluating a Respiratory Syncytial Virus Subunit Vaccine

The elderly are particularly vulnerable to respiratory syncytial virus (RSV) infections, making vaccine development a crucial priority. This study investigates the safety and efficacy of a purified fusion protein (PFP-2) RSV vaccine in frail institutionalized elderly individuals. The researchers conducted an open-label study, finding that the vaccine was well-tolerated and elicited immune responses, although the response rate was somewhat lower compared to healthy elderly individuals. This study underscores the importance of continued research to optimize vaccine efficacy in vulnerable populations.

Weaving a Protective Web: Insights into RSV Vaccine Efficacy in the Elderly

While the vaccine showed promise in this study, it's essential to recognize that further optimization is needed to ensure optimal protection for the frail elderly. This emphasizes the importance of tailored vaccine strategies to address the unique needs of different patient populations.

A Desert Oasis: Ensuring Protection for Vulnerable Individuals

Just as a desert traveler seeks out a reliable water source, the elderly population needs a dependable shield against RSV infections. This study highlights the ongoing quest for effective vaccines for vulnerable individuals, reminding us that research is crucial for creating a healthier future.

Dr.Camel's Conclusion

Protecting the elderly from RSV is like building a sturdy sandcastle on the beach. We need a strong foundation and careful construction to ensure its resilience against the waves of infection. This study provides a valuable step towards that goal, reminding us that we must continue to search for new and improved solutions.

Date :
  1. Date Completed 1997-10-20
  2. Date Revised 2019-07-28
Further Info :

Pubmed ID

9269057

DOI: Digital Object Identifier

10.1016/s0264-410x(97)00002-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.